A 42-year-old woman with MDR-TB (confirmed on MGIT + DST: resistant to INH, RIF, and ofloxacin) is being evaluated for second-line therapy. To exclude XDR-TB and ensure safe use of injectable agents, which investigation is most appropriate?

Explanation

## Investigation of Choice for XDR-TB Confirmation **Key Point:** MGIT culture with DST to second-line drugs (injectables and newer agents) is the standard investigation to confirm XDR-TB phenotype and guide selection of appropriate second-line regimens. ### Why MGIT + DST to Second-Line Drugs? 1. **Definition of XDR-TB** - XDR = MDR + resistance to fluoroquinolone (FQ) + at least one injectable agent (amikacin, kanamycin, or capreomycin). - This patient is already resistant to FQ (ofloxacin); testing for injectable resistance is critical. 2. **Clinical Significance** - If injectable resistance is present → XDR-TB → cannot use standard second-line regimen. - Requires newer agents: bedaquiline, linezolid, delamanid, moxifloxacin (if FQ-susceptible strain exists). - DST results directly inform drug selection and improve treatment outcomes. 3. **Standard of Care** - WHO and NTEP guidelines mandate DST to injectables and newer agents for all MDR-TB cases before finalizing second-line therapy. **High-Yield:** XDR-TB has significantly lower cure rates (~55%) compared to MDR-TB (~65%); early detection via DST is crucial for optimizing therapy. ### Comparison of Investigations for Drug-Resistant TB Confirmation | Investigation | Purpose | Utility in This Case | |---|---|---| | **Sputum smear (ZN)** | Monitors bacterial load | Does NOT detect XDR; cannot guide therapy | | **MGIT + DST (2nd-line)** | **Confirms XDR; identifies injectable resistance** | **GOLD STANDARD; essential for regimen selection** | | **HPLC** | Measures serum drug levels | Useful for monitoring adherence/toxicity, NOT for resistance detection | | **WGS** | Detects resistance-conferring mutations rapidly | Emerging tool; not yet standard in all settings; requires specialized lab | **Clinical Pearl:** A patient with MDR-TB + FQ resistance has ~40% risk of injectable resistance; DST to injectables is mandatory before prescribing them. **Mnemonic:** **XDR = MDR + FQ + Injectable** - Confirm each component via DST to guide therapy. [cite:NTEP TB Guidelines 2022, WHO TB Report 2023]